Expression of annexin A1 in ESCC with different chemoradiotherapy sensitivity and prognostic factors of ESCC

ObjectiveTo study the expression level of annexin A1(ANXA1) in esophageal squamous cell carcinoma(ESCC), and correlations of ANXA1 with chemoradiotherapy sensitivity and prognosis of ESCC.

MethodsThe clinical data of 60 ESCC patients treated with concurrent radiochemotherapy were retrospectively analyzed, and the patients were divided into the chemoradiotherapy sensitive group and chemoradiotherapy resistance group according to the RECIST standard.The expression level of ANXA1 was detected using immunohistochemistry SP method, and the patients were divided into the ANXA1 positive and negative expression groups.The relationship between the expression level of ANXA1, and chemoradiotherapy sensitivity and prognosis of ESCC were analyzed.

ResultsThe positive expression rate of ANXA1 in 60 ESCC tissue samples was 55.0%.The positive ratios of ANXA1 expression in chemoradiotherapy sensitive group and chemoradiotherapy resistance group were 62.8%(22/35) and 44.0%(11/25), respectively, the difference of which was not statistically significant(P>0.05).There was no significant correlation between the expression level of ANXA1, and gender, age, lesion length, T grading, N grading, M grading and clinical staging of ESCC patients(P>0.05).Univariate analysis showed that KPS score, tumor differentiation degree, length of lesion, T grading, N grading, M grading, clinical staging, chemoradiotherapy sensitivity and ANXA1 level were closely related to the prognosis of patients (P < 0.05 to P < 0.01).The multivariate analysis of Cox regression model showed that the KPS score, tumor differentiation degree, clinical staging, chemoradiotherapy sensitivity and ANXA1 level were the independent risk factors affecting the prognosis of ESCC patients(P < 0.05 to P < 0.01).The median total survival time in ANXA1 positive expression group was longer than that in negative expression group(P < 0.05).

ConclusionsThe expression of ANXA1 is not obviously correlated with chemoradiotherapy sensitivity, but is correlated with prognosis of ESCC.The negative expression of ANXA1 suggests the poor outcome of ESCC, and ANXA1 may be an independent risk factor influencing the prognosis of patients with ESCC.